Cargando…
Validation of a comorbidity questionnaire in patients with neurological disorders
RATIONAL: Several tools exist to assess comorbidities in neurological disorders, the most widely used being the Charlson Comorbidity Index (CCI), but it has several limitations. The Comorbidity and General Health Questionnaire (CGHQ) is a newly designed tool, which includes additional comorbidities...
Autores principales: | Vijiaratnam, Nirosen, Vadera, Shree, Lefringhausen, Katharina, Girges, Christine, Schrag, Anette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471876/ https://www.ncbi.nlm.nih.gov/pubmed/37663868 http://dx.doi.org/10.1136/bmjno-2023-000464 |
Ejemplares similares
-
Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
por: Brauer, Ruth, et al.
Publicado: (2020) -
How should we be using biomarkers in trials of disease modification in Parkinson’s disease?
por: Vijiaratnam, Nirosen, et al.
Publicado: (2023) -
Long-term success of low-frequency subthalamic nucleus stimulation for Parkinson’s disease depends on tremor severity and symptom duration
por: Vijiaratnam, Nirosen, et al.
Publicado: (2021) -
The Impact of Type 2 Diabetes in Parkinson's Disease
por: Athauda, Dilan, et al.
Publicado: (2022) -
Diabetes and Neuroaxonal Damage in Parkinson's Disease
por: Vijiaratnam, Nirosen, et al.
Publicado: (2022)